Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02737501
Title	ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)
Acronym	ALTA-1L
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Ariad Pharmaceuticals
Indications	lung non-small cell carcinoma
Therapies	Brigatinib Crizotinib
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| NOR \| NLD \| LUX \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| AUT \| AUS